SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/20/21 Aclaris Therapeutics, Inc. S-3ASR 5/20/21 7:1.3M Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: S-3ASR Automatic Shelf Registration Statement by a HTML 351K Well-Known Issuer 2: EX-4.3 Instrument Defining the Rights of Security Holders HTML 232K 3: EX-4.5 Instrument Defining the Rights of Security Holders HTML 85K 4: EX-4.6 Instrument Defining the Rights of Security Holders HTML 82K 5: EX-4.7 Instrument Defining the Rights of Security Holders HTML 71K 6: EX-5.1 Opinion of Counsel re: Legality HTML 26K 7: EX-23.1 Consent of Expert or Counsel HTML 6K
tm2116900-1_s3asr - none - 5.0781382s |
|
Delaware
|
| |
46-0571712
|
|
|
(State or other jurisdiction
of incorporation or organization) |
| |
(I.R.S. Employer
Identification Number) |
|
| | | |
|
Large accelerated filer
☐
|
| |
Accelerated filer
☐
|
|
|
Non-accelerated filer
☒
|
| |
Smaller reporting company
☒
|
|
| | | |
Emerging growth company
☐
|
|
| | | ||||||||||||||||||||||||||||
|
Title of Each Class of Securities to be Registered
|
| | |
Amount
to be Registered |
| | |
Proposed
Maximum Offering Price Per Unit |
| | |
Proposed
Maximum Aggregate Offering Price |
| | |
Amount of
Registration Fee |
| ||||||||||||
| Securities covered by the base prospectus included herein: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|
Common Stock, par value $0.00001 per share
|
| | | |
|
(1)
|
| | | | |
|
(1)
|
| | | | |
|
(1)
|
| | | | |
|
(2)
|
| |
|
Preferred Stock, par value $0.00001 per share
|
| | | |
|
(1)
|
| | | | |
|
(1)
|
| | | | |
|
(1)
|
| | | | |
|
(2)
|
| |
|
Debt Securities
|
| | | |
|
(1)
|
| | | | |
|
(1)
|
| | | | |
|
(1)
|
| | | | |
|
(2)
|
| |
|
Warrants
|
| | | |
|
(1)
|
| | | | |
|
(1)
|
| | | | |
|
(1)
|
| | | | |
|
(2)
|
| |
| Securities covered by the sales agreement prospectus included herein: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|
Common Stock, par value $0.00001 per share
|
| | | |
|
(3)
|
| | | | |
|
(3)
|
| | | | | $ | 150,000,000.00 | | | | | | $ | 16,365.00(4) | | |
| | | | | ii | | | |
| | | | | 1 | | | |
| | | | | 4 | | | |
| | | | | 5 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 13 | | | |
| | | | | 20 | | | |
| | | | | 22 | | | |
| | | | | 25 | | | |
| | | | | 26 | | | |
| | | | | 27 | | | |
| | | | | 27 | | | |
| | | | | 28 | | | |
| | | | | 29 | | |
| | |
Page
|
| |||
| | | | S-ii | | | |
| | | | S-1 | | | |
| | | | S-3 | | | |
| | | | S-4 | | | |
| | | | S-5 | | | |
| | | | S-7 | | | |
| | | | S-8 | | | |
| | | | S-10 | | | |
| | | | S-14 | | | |
| | | | S-15 | | | |
| | | | S-15 | | | |
| | | | S-15 | | | |
| | | | S-16 | | |
|
Assumed public offering price per share
|
| | | | | | | | | $ | 22.97 | | |
|
Net tangible book value per share of as March 31, 2021
|
| | | $ | 2.02 | | | | | | | | |
|
Increase in net tangible book value per share attributable to this offering
|
| | | | 2.25 | | | | | | | | |
|
As adjusted net tangible book value per share as of March 31, 2021, after giving effect to this offering
|
| | | | | | | | | | 4.27 | | |
|
Dilution per share to investors purchasing our common stock in this offering
|
| | | | | | | | | $ | 18.70 | | |
|
SEC registration fee
|
| | | $ | 16,365(1) | | |
|
FINRA filing fee (if applicable)
|
| | |
|
(2)
|
| |
|
Accounting fees and expenses
|
| | |
|
(2)
|
| |
|
Legal fees and expenses
|
| | |
|
(2)
|
| |
|
Transfer agent fees and expenses
|
| | |
|
(2)
|
| |
|
Trustee fees and expenses
|
| | |
|
(2)
|
| |
|
Printing and miscellaneous expenses
|
| | |
|
(2)
|
| |
|
Total
|
| | | $ | (2) | | |
| | | | ACLARIS THERAPEUTICS, INC. | |
| | | |
By:
/s/ Neal Walker
Neal Walker
President and Chief Executive Officer |
|
|
Signature
|
| |
Title
|
| |
Date
|
|
|
/s/ Neal Walker
|
| |
President, Chief Executive Officer and Director
(Principal Executive Officer) |
| | | |
|
/s/ Frank Ruffo
|
| |
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)
|
| | | |
|
|
| | Chairman of the Board of Directors | | | | |
|
|
| | Director | | | | |
|
|
| | Director | | | | |
|
/s/ Andrew Powell
|
| | Director | | | | |
|
/s/ Andrew Schiff
|
| | Director | | | | |
|
/s/ Bryan Reasons
|
| | Director | | | | |
|
/s/ Maxine Gowen
|
| | Director | | | | |
|
/s/ Vincent Milano
|
| | Director | | | |
This ‘S-3ASR’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on / Effective on: | 5/20/21 | 8-K | ||
5/19/21 | ||||
3/31/21 | 10-Q | |||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/20/21 Aclaris Therapeutics, Inc. 8-K:1,9 5/20/21 11:480K Toppan Merrill/FA 5/07/21 Aclaris Therapeutics, Inc. 10-Q 3/31/21 72:6.7M Toppan Merrill Bridge/FA 4/22/21 Aclaris Therapeutics, Inc. DEF 14A 6/03/21 1:855K Toppan Merrill Bridge/FA 2/25/21 Aclaris Therapeutics, Inc. 10-K 12/31/20 104:12M Toppan Merrill Bridge/FA 1/19/21 Aclaris Therapeutics, Inc. 8-K:7,8,9 1/19/21 12:5.3M Toppan Merrill Bridge/FA 6/24/20 Aclaris Therapeutics, Inc. 8-K:5,9 6/23/20 2:181K Toppan Merrill Bridge/FA 10/13/15 Aclaris Therapeutics, Inc. 8-K:5 10/13/15 3:240K Toppan Merrill/FA 10/02/15 Aclaris Therapeutics, Inc. 8-A12B 1:23K Toppan Merrill/FA 9/25/15 Aclaris Therapeutics, Inc. S-1/A 15:4.9M Toppan Merrill-FA |